Aytu BioPharma Inc (LTS:0A8M)
$ 1.8172 0 (0%) Market Cap: 10.70 Mil Enterprise Value: 7.15 Mil PE Ratio: 0 PB Ratio: 0.36 GF Score: 34/100
Back to the Transcripts List

Q1 2025 Aytu Biopharma Inc Earnings Call Transcript

Nov 13, 2024 / 09:30 PM GMT
Release Date Price: $1.77 (-1.67%)

Key Points

Positve
  • Aytu BioPharma Inc (AYTU) reported its first quarter with positive net income in the company's history.
  • The company achieved its sixth consecutive quarter of positive adjusted EBITDA.
  • ADHD script levels are above normalized trend lines, indicating growth in the ADHD portfolio.
  • The pediatric portfolio saw its first sequential revenue growth in the last five quarters.
  • Organizational changes are expected to reduce operating expenses by at least $2 million annually.
Negative
  • Net revenue decreased to $16.6 million from $17.8 million in the year-ago quarter.
  • Pediatric revenue was down to $1.3 million from $2.6 million compared to the previous year.
  • Gross margin slightly decreased to 72% from 73% in the previous year.
  • There is expected noise in gross margins for the next several quarters due to inventory costs.
  • The company is still recovering from the impact of payer changes on its pediatric brands.


Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

AYTU.OQ - Aytu Biopharma Inc
Q1 2025 Aytu Biopharma Inc Earnings Call
Nov 13, 2024 / 09:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Greetings, welcome to the A two BioPharma fiscal 2025 Q1 earnings conference call. At this time, all participants are in a listen-only mode, a question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. Please note that this conference is being recorded. I will now turn the conference over to your host, Robert Bloom with listen partners. You may begin.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
All right. Thank you very much, Mike. Good afternoon, everyone. And
Already have an account? Log in
Get the full story
Start 7-Day Free Trial
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot
Research Tools
All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board
Product
Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文
Education
Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation
Company
About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program
Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey
Follow Us
download GuruFocus on Apple store download GuruFocus on Google Play
Disclaimers
GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.
© 2004-2025 GuruFocus.com, LLC. All Rights Reserved.